{"doi":"10.18632/oncotarget.28610","title":"Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity","abstract":null,"journal":"Oncotarget","year":2024,"id":603046,"datarank":0.31191623125197543,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"self_citation_contribution":0.31191623125197543,"citation_network_contribution":0.0,"self_endowment_contribution":0.31191623125197543,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1546850,"name":"Lara V. Graham","orcid":null,"position":1,"is_corresponding":false},{"id":1546852,"name":"Matthew D. Blunt","orcid":null,"position":2,"is_corresponding":false},{"id":1546848,"name":"Jack G. Fisher","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity","abstract":null,"is_dataset_classified":null,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39018202","pmcid":"PMC11254306","openalex_id":"https://openalex.org/W4400731230","authors":[],"funders":[],"total_grants":0,"fwci":0.9463,"citation_percentile":0.73060505,"influential_citations":0,"citation_trend":[{"year":2025,"count":2},{"year":2026,"count":4}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://doi.org/10.18632/oncotarget.28610","host_type":"journal"},{"url":"https://doi.org/10.18632/oncotarget.28610","host_type":"publisher"},{"url":"https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.28610","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39018202","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11254306","host_type":"repository"},{"url":"https://eprints.soton.ac.uk/492842/","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11254306/pdf/oncotarget-15-28610.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC11254306","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC11254306?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Immune Cell Function and Interaction","T-cell and B-cell Immunology","CAR-T cell therapy research"],"mesh_terms":["HLA-E Antigens","Animals","Humans","Killer Cells, Natural","Neoplasms","Histocompatibility Antigens Class I","NK Cell Lectin-Like Receptor Subfamily C"],"keywords":["Medicine","Immunology","Immunity","Cancer","Human leukocyte antigen","Immune system","Cancer research","Antigen","Internal medicine","Immunotherapy","HLA-E","NKG2A","Natural Killer (Nk) Cells","Immune Checkpoint Blockade"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-29T20:57:33.453399Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}